|

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

RECRUITINGSponsored by Abramson Cancer Center at Penn Medicine
Actively Recruiting
SponsorAbramson Cancer Center at Penn Medicine
Started2018-09-21
Est. completion2026-06-22
Eligibility
Age60 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT03680677

Summary

The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.

Eligibility

Age: 60 Years+Healthy volunteers accepted
Eligibility Criteria Arm A:

* Age 60 years or older.
* New diagnosis of Acute Leukemia or MDS, or suspected diagnosis.
* Able to consent to the study.

Eligibility Criteria Arm B:

* Age 60 years or older with a hematologic malignancy.
* Plan to undergo an allogeneic blood or marrow transplantation or CAR T-cell therapy.
* Able to consent to the study.

Conditions3

CancerLeukemia, AcuteMDS

Locations1 site

Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.